Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Dusquetide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Soligenix Gains MHRA PIM Designation for SGX945
    Soligenix Gains MHRA PIM Designation for SGX945

    10 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-announces-sgx945-receives-promising-innovative-medicine-designation-from-the-uk-medicines-and-healthcare-products-regulatory-agency-302709102.html

    PR NEWSWIRE
    10 Mar 2026
    Share Share
    Soligenix SGX945 Gets EMA Orphan Designation for Behçet's Disease
    Soligenix SGX945 Gets EMA Orphan Designation for Behçet's Disease

    26 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-receives-positive-opinion-from-the-european-medicines-agency-on-the-request-for-orphan-drug-designation-for-sgx945-for-the-treatment-of-behcets-disease-302698032.html

    PR NEWSWIRE
    26 Feb 2026
    Share Share
    SGX945 Phase 2 Trial Shows Promising Results In Behçet's Disease
    SGX945 Phase 2 Trial Shows Promising Results In Behçet's Disease

    18 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/positive-clinical-results-from-phase-2-trial-of-sgx945-for-the-treatment-of-behcets-disease-published-in-rheumatology-oxford-302645452.html

    PR NEWSWIRE
    18 Dec 2025
    Share Share
    Soligenix Launches Phase 2 Trial for SGX945 in Behçet's Disease
    Soligenix Launches Phase 2 Trial for SGX945 in Behçet's Disease

    14 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of-behcets-disease-302305230.html

    PR NEWSWIRE
    14 Nov 2024
    Share Share
    FDA Grants Soligenix
    FDA Grants Soligenix "Fast Track" Designation for Dusquetide

    08 Jan 2024

    // PRESS RELEASE

    https://ir.soligenix.com/2024-01-08-FDA-Grants-Soligenix-Fast-Track-Designation-for-Dusquetide-in-the-Treatment-of-Oral-Lesions-of-Behcets-Disease

    PRESS RELEASE
    08 Jan 2024
    Share Share
    Key Binding Characteristics of Dusquetide to Intracellular Protein Identified
    Key Binding Characteristics of Dusquetide to Intracellular Protein Identified

    01 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/key-binding-characteristics-of-dusquetide-to-important-intracellular-protein-identified-301558732.html

    PRNEWSWIRE
    01 Jun 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.